Clinical epigenetics and multidrug-resistant bacterial infections: host remodelling in critical illness
- 14 April 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Epigenetics
- Vol. 15 (10), 1021-1034
- https://doi.org/10.1080/15592294.2020.1748918
Abstract
The inappropriate use of antibiotics in man is driving to insurgence of pathogenic bacteria resistant to multiple drugs (MDR) representing a challenge in critical illness. The interaction of MDR bacteria with host cells can guide molecular perturbations of host transcriptional programmes involving epigenetic-sensitive mechanisms, mainly DNA methylation, histone modifications, and non-coding RNAs leading to pathogen survival. Clinical evidence of epigenetic manipulation from MDR bacteria mainly arises from Mycobacterium tuberculosis as well as Helicobacter pylori, Escherichia coli, Listeria monocytogenes, Pseudomonas aeruginosa, and Legionella pneumophila infection suggesting possible biomarkers of disease. For example, DNA hypermethylation of E-cadherin (CDH1), upstream transcription factor 1/2 (USF1/2), WW domain containing oxidoreductase (WWOX), and mutL homolog 1 (MLH1) genes in gastric mucosa is correlated with malignancy suggesting useful biomarkers of early disease state. Moreover, upregulated circulating miR-361-5p, miR-889, miR-576-3p may be useful biomarkers to discriminate tuberculosis patients. Moreover, Listeria monocytogenes can indirectly induce H3 hyperacetylation leading to inflammation in human endothelial cells whereas Pseudomonas aeruginosa excretes QS 2-AA to directly induce H3 deacetylation leading to bacterial persistence in human monocytes. Remarkably, epigenetic-sensitive drugs may aid to counteract MDR in clinical setting. Trichostatin A, a histone deacetyltransferase inhibitor (HDACi), leads to AMP β-defensin 2 (HBD2) gene up-regulation in human epithelial cells suggesting a useful ‘epi-therapy’ for Escherichia coli-induced intestinal diseases. We update on the most current clinical studies focusing on epigenetic changes involved in bacterial-host interactions and their putative role as biomarkers or drug targets to improve precision medicine and personalized therapy in critical illness and transplantation setting.Keywords
Funding Information
- Italian Ministry of Research (PRIN2017F8ZB89)
This publication has 74 references indexed in Scilit:
- Programmed Heterogeneity: Epigenetic Mechanisms in BacteriaOnline Journal of Public Health Informatics, 2013
- Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infectionBMC Infectious Diseases, 2012
- Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytesProceedings of the National Academy of Sciences of the United States of America, 2012
- Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of MonocytesCell Host & Microbe, 2012
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology & Infection, 2012
- Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancerBiochemical and Biophysical Research Communications, 2011
- H. pylori-induced promoter hypermethylation downregulates USF1 and USF2 transcription factor gene expressionCellular Microbiology, 2010
- DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defectInternational Journal of Cancer, 2009
- Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine TailDiabetes, 2009